NextCure stock: ADAR1 funds report purchases totaling 10,851 shares
Published on 10/30/2026 at 02:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSInsider purchases add a new angle
- ADAR1-managed funds reported purchases on October 23, October 26 and October 27, 2026.
- The filing identifies ADAR1 Capital Management and Daniel Schneeberger as directors and 10% owners.
- The reported holdings rose to 733,270 shares after the transactions, subject to the filing's ownership disclaimers.
Funds managed by ADAR1 Capital Management reported purchases of NextCure common stock in transactions dated October 23, October 26 and October 27, 2026. The Form 4 filing was signed and filed on October 27, according to the StockTitan filing page reproducing the SEC Form 4.
Three purchase dates
The filing reports 5,626 shares at a weighted-average price of 4.8294 US dollars on October 23, followed by 1,672 shares at 5.0344 US dollars on October 26 and 3,553 shares at 5.0953 US dollars on October 27. The respective transaction price ranges were 4.72 to 4.90 US dollars, 5.00 to 5.10 US dollars and 4.99 to 5.10 US dollars.
After the reported transactions, the holdings listed for the common stock totaled 733,270 shares. The securities are held indirectly through private investment funds managed by ADAR1 Capital Management. The filing says ADAR1 and Daniel Schneeberger may be deemed indirect beneficial owners, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
What investors should note
The disclosure identifies ADAR1 Capital Management and Daniel Schneeberger as a director and 10% owner. It does not by itself establish why the purchases were made or indicate that the transactions predict a future share-price move. The filing also reports no Rule 10b5-1 plan for the purchases.
NextCure remains a clinical-stage biotechnology company developing immunomedicines for cancer and immune-related diseases. The company says on its investor-relations website that its focus is on restoring normal immune function.
NextCure company and filing data
- Company: NextCure, Inc.
- ISIN: US65343E2072
- Ticker: NXTC
- Sector: Healthcare
- Industry: Biotechnology
- Reported purchases: 10,851 common shares across three transactions
- Filing date: October 27, 2026
US biotechnology shares are generally assessed against the broader US equity market, without implying that NextCure is a member of the index; see the S&P 500 market theme.
More filings and company developments are available in More news and analyses on NextCure stock.
